Tirzepatide
Studied for: dual receptor research
Tirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors. Research examines whether combining the two incretin pathways differs from GLP-1 agonism alone.
Last reviewed September 26, 2026
How it is thought to work
Research investigates tirzepatide across both incretin receptors, studied for combined effects on insulin signaling, gastric emptying, and satiety.
- Dual IncretinStudied at both GIP and GLP-1 receptors, the GIP component distinguishing it from single agonists.
- Metabolic SignalingExplored for effects across glucose handling and appetite regulation together.
- Route studied
- Subcutaneous
- Receptor class
- GLP-1R / GIPR
- Research status
- Late clinical
Tirzepatide has been evaluated in multiple randomized phase 3 trials, including SURPASS-1, SURPASS-2 against semaglutide, and SURMOUNT-4, with phase 2 work in liver disease and a cardiovascular outcomes trial also underway.
Research
What the research covers
What research examines
- Glycemic control in type 2 diabetes trials
- Weight reduction and weight maintenance in adults with obesity
- Appetite, energy intake, and fat mass
- Head-to-head comparison with semaglutide
- Metabolic dysfunction-associated steatohepatitis with liver fibrosis
- Cardiovascular outcomes compared with dulaglutide
Reported effects in studies
- Safety was a primary focus of phase 3 trials such as SURPASS-1, though specific adverse event rates are not summarized here
- Cardiovascular safety is being assessed against dulaglutide in the SURPASS-CVOT trial
- Studied for effects on gastric emptying as part of its mechanism
- Long-term safety outside controlled trial settings is not characterized in this overview
Studied range
What research protocols have used
Research protocols have used 1.5–15 mg per administration, once weekly (morning, fasted), stepping up from 2.5 mg to 10 mg by week 13. Reported cycle: continuous until target weight loss.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- MOTS-cMOTS-c is a peptide encoded in mitochondrial DNA. Research examines its role as a signal between the mitochondria and the nucleus, particularly under metabolic stress.Read profile$99
- GLP-3RGLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors. Research examines whether engaging all three affects metabolic regulation differently to dual or single agonists.Read profile$119
- AOD-9604AOD 9604 is a synthetic peptide derived from the C-terminal fragment of human growth hormone, isolated for research into fat metabolism without the broader activity of the full hormone.Read profile$89
- 5-Amino-1MQ5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase, an enzyme associated with fat-cell metabolism and cellular NAD+ availability.Read profile$89
Studies
Cited research
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Lancet (London, England) · 2021 · RCT · PMID 34186022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
The New England journal of medicine · 2021 · RCT · PMID 34170647
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA · 2024 · RCT · PMID 38078870
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
JCI insight · 2020 · PMID 32730231
- Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Diabetes care · 2023 · RCT · PMID 36857477
FAQ
Questions about Tirzepatide
Tirzepatide is a peptide studied as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Research examines whether engaging both incretin pathways produces effects that differ from GLP-1 agonism alone. It has been evaluated in large randomized clinical trials in type 2 diabetes and obesity, and in smaller trials exploring liver disease and cardiovascular outcomes.
Tirzepatide is studied at both the GIP and GLP-1 receptors, and its GIP activity distinguishes it from single-receptor GLP-1 agonists. Research has explored its combined effects on insulin signaling, gastric emptying, and satiety. Mechanistic work published in JCI Insight described it as an imbalanced and biased dual agonist, meaning its activity at the two receptors and their downstream signaling pathways is not equivalent.
Phase 3 trials have examined glycemic control in type 2 diabetes, including SURPASS-1 and a head-to-head comparison with semaglutide. The SURMOUNT-4 trial studied continued use for maintenance of weight reduction in adults with obesity, and a later trial compared it with semaglutide for obesity. Other studies have examined appetite, energy intake, and fat mass, liver fibrosis in steatohepatitis, and cardiovascular events versus dulaglutide.
Safety was assessed alongside efficacy in phase 3 trials such as SURPASS-1, and cardiovascular safety is being evaluated against dulaglutide in the SURPASS-CVOT trial. Specific adverse event types and rates are not summarized in this overview. Because the compound acts on gastric emptying as part of its studied mechanism, gastrointestinal effects are an area of research attention. Researchers should consult the primary trial publications for detailed safety findings.
Research protocols have used 1.5 to 15 mg per administration, given subcutaneously once weekly (morning, fasted), stepping up from 2.5 mg to 10 mg by week 13. The reported cycle was continuous until target weight loss. These figures describe what published protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.
Ask about Tirzepatide
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- GLP-3R vs TirzepatideGLP-3R and Tirzepatide are both incretin-based research peptides studied for metabolic regulation and administered subcutaneously in research protocols. GLP-3R is studied as a triple agonist at the GLP-1, GIP, and glucagon receptors, while Tirzepatide is studied as a dual agonist at the GLP-1 and GIP receptors. The glucagon receptor component is the main mechanistic distinction, and research explores whether it contributes an energy expenditure effect alongside appetite signaling. GLP-3R has been studied for body weight reduction in obesity, glycemic control in type 2 diabetes, and liver fat in metabolic dysfunction-associated steatotic liver disease. Tirzepatide has been evaluated in multiple phase 3 trials for glycemic control, weight reduction and maintenance, and a head-to-head comparison with semaglutide.
- Semaglutide vs TirzepatideSemaglutide and Tirzepatide are both incretin-based compounds studied in metabolic research, and both have been investigated as once-weekly subcutaneous agents. Semaglutide is a long-acting GLP-1 receptor agonist whose structural modifications extend its half-life. Research has examined its role in glucose-dependent insulin signaling, gastric emptying, satiety pathways, and weight loss in obesity without diabetes. Tirzepatide is studied as a dual agonist at the GIP and GLP-1 receptors, and research asks whether adding the GIP component differs from GLP-1 agonism alone. Its phase 3 program has examined glycemic control in type 2 diabetes, weight reduction and maintenance in adults with obesity, and a head-to-head comparison with semaglutide in SURPASS-2.